204 related articles for article (PubMed ID: 31318041)
21. Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
Valenzuela F; Papp KA; Pariser D; Tyring SK; Wolk R; Buonanno M; Wang J; Tan H; Valdez H
BMC Dermatol; 2015 May; 15():8. PubMed ID: 25951857
[TBL] [Abstract][Full Text] [Related]
22. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
Menter A; Papp KA; Tan H; Tyring S; Wolk R; Buonanno M
J Drugs Dermatol; 2014 Mar; 13(3):252-6. PubMed ID: 24595567
[TBL] [Abstract][Full Text] [Related]
24. Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children.
AlMutairi N; Nour T
Dermatology; 2020; 236(3):191-198. PubMed ID: 31665730
[TBL] [Abstract][Full Text] [Related]
25. Oral small molecules for psoriasis.
Singh S; Armstrong AW
Semin Cutan Med Surg; 2018 Sep; 37(3):163-166. PubMed ID: 30215633
[TBL] [Abstract][Full Text] [Related]
26. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
Bushmakin AG; Mamolo C; Cappelleri JC; Stewart M
J Dermatolog Treat; 2015 Feb; 26(1):19-22. PubMed ID: 24289224
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation.
Li Y; Huo J; Cao Y; Yu M; Zhang Y; Li Z; Li C; Zhang W
Ann Rheum Dis; 2020 Sep; 79(9):1255-1257. PubMed ID: 32332076
[No Abstract] [Full Text] [Related]
28. Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
Ports WC; Feldman SR; Gupta P; Tan H; Johnson TR; Bissonnette R
J Drugs Dermatol; 2015 Aug; 14(8):777-84. PubMed ID: 26267721
[TBL] [Abstract][Full Text] [Related]
29. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
Mrowietz U; Gerdes S; Gläser R; Schröder O
Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
[No Abstract] [Full Text] [Related]
30. Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis.
Wu JJ; Strober BE; Hansen PR; Ahlehoff O; Egeberg A; Qureshi AA; Robertson D; Valdez H; Tan H; Wolk R
J Am Acad Dermatol; 2016 Nov; 75(5):897-905. PubMed ID: 27498960
[TBL] [Abstract][Full Text] [Related]
31. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
Di Lernia V; Bardazzi F
Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
[TBL] [Abstract][Full Text] [Related]
32. Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis.
Komai T; Shoda H; Hanata N; Fujio K
Scand J Rheumatol; 2018 Nov; 47(6):505-506. PubMed ID: 29260607
[No Abstract] [Full Text] [Related]
33. Topical tofacitinib in treatment of alopecia areata.
Ferreira SB; Ferreira RB; Scheinberg MA
Einstein (Sao Paulo); 2020; 18():eAI5452. PubMed ID: 32785452
[No Abstract] [Full Text] [Related]
34. Alopecia universalis. Partial response to tofacitinib.
Ruiz-Villaverde R; Cuenca-Barrales C; Linares-Gonzalez L; Ródenas-Herranz T
Med Clin (Barc); 2019 Aug; 153(3):e15. PubMed ID: 30718001
[No Abstract] [Full Text] [Related]
35. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
[TBL] [Abstract][Full Text] [Related]
36. A pilot study of tofacitinib for refractory Behçet's syndrome.
Liu J; Hou Y; Sun L; Li C; Li L; Zhao Y; Zeng X; Zhang F; Zheng W
Ann Rheum Dis; 2020 Nov; 79(11):1517-1520. PubMed ID: 32461206
[No Abstract] [Full Text] [Related]
37. A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.
Sato S; Matsumoto H; Temmoku J; Fujita Y; Matsuoka N; Furuya M; Gunji N; Fujiwara T; Asano T; Onizawa M; Kobayashi H; Watanabe H; Ohira H; Migita K
Rheumatology (Oxford); 2020 Jul; 59(7):1773-1775. PubMed ID: 31776552
[No Abstract] [Full Text] [Related]
38. Serum Human Beta-Defensin-2 Is a Possible Biomarker for Monitoring Response to JAK Inhibitor in Psoriasis Patients.
Jin T; Sun Z; Chen X; Wang Y; Li R; Ji S; Zhao Y
Dermatology; 2017; 233(2-3):164-169. PubMed ID: 28654918
[TBL] [Abstract][Full Text] [Related]
39. Pregnancy outcomes following tofacitinib use for synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: Case report.
Zhang C; Shi X; Ding Y; Lin Z; Qian T; Liu X; Hou X; Li C
Int J Rheum Dis; 2024 Jun; 27(6):e15209. PubMed ID: 38873853
[No Abstract] [Full Text] [Related]
40. Tofacitinib for familial Mediterranean fever: a new alternative therapy?
Garcia-Robledo JE; Aragón CC; Nieto-Aristizabal I; Posso-Osorio I; Cañas CA; Tobón GJ
Rheumatology (Oxford); 2019 Mar; 58(3):553-554. PubMed ID: 30535114
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
